Current scenario of drug development for leishmaniasis

Croft, SL; Seifert, K; Yardley, V; (2006) Current scenario of drug development for leishmaniasis. The Indian journal of medical research, 123 (3). pp. 399-410. ISSN 0971-5916

Text - Published Version

Download (148kB) | Preview


Although three new drugs or drug formulations, liposomal amphotericin B (AmBisome), miltefosine and paromomycin should be available for the treatment of visceral leishmaniasis (VL) within the next year, they all suffer from limitations of either cost, specific toxicities or parenteral administration. As part of research to identify better treatments for VL and cutaneous leishmaniasis (CL), alternative and potentially cheaper formulations of amphotericin B, alklyphosphocholines other than miltefosine and improved formulations of paromomycin for CL have been identified. Other drugs or compounds that have demonstrated activity in experimental rodent models of infection include licochalcone derivatives, quinoline derivatives, bisphosphonates and a maesabalide; further chemistry based upon these leads is warranted. The process for discovery and development of new antileishmanials would also benefit from improved models, for example, transfected parasites, and non invasive methods of measuring parasite load in rodent models of infection.

Item Type: Article
Keywords: amphotericin B, cutaneous leishmaniasis, first line drugs, miltefosine, toxicity, visceral leishmaniasis, Liposomal amphotericin-b, world cutaneous leishmaniasis, sodium, stibogluconate pentostam, stage-specific activity, in-vivo activities, real-time pcr, visceral leishmaniasis, donovani promastigotes, topical, treatment, hexadecylphosphocholine miltefosine
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Immunology and Infection
Research Centre: Antimicrobial Resistance Centre (AMR)
Leishmaniasis Group
Malaria Centre
Neglected Tropical Diseases Network
PubMed ID: 16778319
Web of Science ID: 238243500018


Download activity - last 12 months
Downloads since deposit
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item